What are the indications for the Dexcom G5 Mobile Continuous Glucose Monitoring System (CGM) system?

Updated: Jan 22, 2020
  • Author: Benjamin Daniel Liess, MD; Chief Editor: George T Griffing, MD  more...
  • Print


In December 2016, the FDA expanded its approval of the Dexcom G5 Mobile Continuous Glucose Monitoring System (CGM) system as a replacement for traditional fingerstick testing in adults and children aged 2 years or older. This was the first CGM system that can be used for diabetes-related treatment decisions without use of a traditional fingerstick test for confirmation. [1, 2]

Since the initial introduction, many different devices have become available with variable accuracy and reliability of results. [3] Future devices may utilize nanoparticle sensors to determine the physiological range as a tool for real-time glucose tracking. [4] CGM technology is underprescribed and, if better utilized, could provide better hemoglobin A1c (HbA1c) control and decrease the incidence of diabetic complications. CGM is very helpful for patients with hypoglycemia unawareness and nocturnal hypoglycemia.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!